The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study

Keyphrases

• 5-year Follow-up 100%
• Additional Treatment 10%
• Aminosalicylates 100%
• Biological Therapy 10%
• Clinical Data 10%
• Clinical Practice 10%
• Community-based 20%
• Crohn's Disease 100%
• Death Rate 10%
• Disease Activity 10%
• Disease Course 40%
• European Community 20%
• First Year 20%
• Gastroenterologist 10%
• Hospitalization 10%
• Immunomodulator 10%
• Inception Cohort 100%
• Intensive Care Medicine 10%
• Medical Therapy 10%
• Mild Disease 10%
• Monotherapy 30%
• Patient Management 10%
• Penetrating Disease 10%
• Quiescent Infection 10%
• Stricturing Disease 10%
• Surgery Rates 10%

Medicine and Dentistry

• Biological Therapy 10%
• Cancer Surgery 10%
• Combination Therapy 10%
• Crohn's Disease 20%
• Disease 20%
• Disease Activity 10%
• Disease Course 40%
• Immunomodulating Agent 10%
• Inflammatory Bowel Disease 100%
• Intensive Care 10%
• Maintenance Therapy 10%
• Mesalazine 100%
• Monotherapy 30%
• Patient Care 10%
• Patient with Crohn's Disease 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Aminosalicylic Acid 100%
• Combination Therapy 10%
• Crohn's Disease 100%
• Disease 20%
• Disease Activity 10%
• Disease Course 40%
• Immunomodulating Agent 10%
• Inflammatory Bowel Disease 100%
• Malignant Neoplasm 10%
• Monotherapy 30%